PTD-DBM
Also known as: PTD-DBM
Chemical identity verified against PubChem/patent/analytical records. One PubChem CID mapping is inconsistent across sources (reported 176453931 vs 176453176) — confirm the database ID before final import. Product-level verification still requires an exact-lot COA with HPLC + MS/LC-MS.
Molecular Overview
PTD-DBM is a 25-amino-acid peptide combining a polyarginine protein-transduction domain with a Dishevelled-binding motif, studied in preclinical Wnt-pathway research. Analytical records report a theoretical mass of ~3082.65 Da and an observed mass of ~3082.80 Da for the specified sequence.
Mechanistic Background
Designed to engage the Dishevelled protein interaction within Wnt signalling; characterization is preclinical and experimental.
What Researchers Study
Preclinical research has examined Wnt-pathway/Dishevelled-related endpoints in experimental models.
Evidence Landscape
Current evidence level: PRECLINICAL. Preclinical evidence does not equate to demonstrated human efficacy.
Research Limitations
Evidence is preclinical. Confirm the PubChem database mapping and retain an exact-lot COA (HPLC + MS/LC-MS, lot number, testing laboratory) before an inventory lot is marked fully verified.
Scientific References
Research Use Only
Molecularix Biolabs provides research materials for legitimate laboratory research. Information in this Research Library is provided for educational and scientific reference purposes and is not medical advice, treatment guidance, or a recommendation for human or veterinary use.